MX2021014015A - Metodos basados en el genoma para reducir el riesgo cardiovascular. - Google Patents

Metodos basados en el genoma para reducir el riesgo cardiovascular.

Info

Publication number
MX2021014015A
MX2021014015A MX2021014015A MX2021014015A MX2021014015A MX 2021014015 A MX2021014015 A MX 2021014015A MX 2021014015 A MX2021014015 A MX 2021014015A MX 2021014015 A MX2021014015 A MX 2021014015A MX 2021014015 A MX2021014015 A MX 2021014015A
Authority
MX
Mexico
Prior art keywords
cardiovascular risk
genome
based methods
reducing cardiovascular
pcsk9 inhibitor
Prior art date
Application number
MX2021014015A
Other languages
English (en)
Inventor
Amy Damask
Aris Baras
Goncalo Abecasis
Charles Paulding
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021014015A publication Critical patent/MX2021014015A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

La presente descripción proporciona métodos para reducir el riesgo cardiovascular mediante la administración de un inhibidor de la PCSK9 a pacientes que tienen un perfil genético relacionado con la respuesta a la terapia con el inhibidor de la PCSK9.
MX2021014015A 2019-05-17 2020-05-16 Metodos basados en el genoma para reducir el riesgo cardiovascular. MX2021014015A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962849670P 2019-05-17 2019-05-17
US201962933181P 2019-11-08 2019-11-08
PCT/US2020/033315 WO2020236670A1 (en) 2019-05-17 2020-05-16 Genome-based methods for reducing cardiovascular risk

Publications (1)

Publication Number Publication Date
MX2021014015A true MX2021014015A (es) 2022-02-21

Family

ID=70978651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014015A MX2021014015A (es) 2019-05-17 2020-05-16 Metodos basados en el genoma para reducir el riesgo cardiovascular.

Country Status (6)

Country Link
US (1) US20210002724A1 (es)
EP (1) EP3969620A1 (es)
JP (1) JP2022532423A (es)
CA (1) CA3139943A1 (es)
MX (1) MX2021014015A (es)
WO (1) WO2020236670A1 (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101636179B (zh) 2006-11-07 2012-10-10 默沙东公司 Pcsk9拮抗剂
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2493505A4 (en) 2009-10-30 2013-06-12 Merck Sharp & Dohme AX1 AND AX189 PCSK9 ANTAGONISTS AND VARIANTS THEREOF
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
KR20120138241A (ko) 2010-03-11 2012-12-24 화이자 인코포레이티드 ｐＨ 의존성 항원 결합을 갖는 항체
CN103476797A (zh) 2011-01-28 2013-12-25 赛诺菲 包含针对pcsk9的人抗体的药物组合物
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2861624A1 (en) 2012-06-15 2015-04-22 F. Hoffmann-La Roche AG Anti-pcsk9 antibodies, formulations, dosing, and methods of use
CA2881679C (en) 2012-08-13 2021-01-26 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
CA2904662A1 (en) 2013-03-15 2014-09-25 Shifa Biomedical Corporation Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US10329620B2 (en) * 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
US20190017119A1 (en) * 2017-07-12 2019-01-17 The General Hospital Corporation Genetic Risk Predictor

Also Published As

Publication number Publication date
US20210002724A1 (en) 2021-01-07
CA3139943A1 (en) 2020-11-26
EP3969620A1 (en) 2022-03-23
WO2020236670A1 (en) 2020-11-26
JP2022532423A (ja) 2022-07-14

Similar Documents

Publication Publication Date Title
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
GEP201706768B (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
MX2016010504A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas.
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
TN2012000280A1 (en) Methods of administering pirfenidone therapy
NZ720478A (en) Autotaxin inhibitor compounds
NZ594365A (en) Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders
GEP20186864B (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
CR20200228A (es) COMPOSICIONES Y MÈTODOS PARA MODULAR LA EXPRESIÒN DEL FACTOR B DEL COMPLEMENTO (Divisional 2016-0554)
EA201491701A1 (ru) Лечение рака ингибиторами tor киназы
MX2021015210A (es) Inhibidores de la via de respuesta al estres integrada.
EP3822352A3 (en) Methods and compositions for modulating apolipoprotein(a) expression
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
MX2020013269A (es) Inhibidores de la vía de respuesta al estrés integrada.
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
WO2018148071A8 (en) Combination therapy for treating disorders of the ear
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
MX2018005277A (es) Modular la expresion de apolipoproteina (a).
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX365464B (es) Prodecimiento para preparar inhibidores de la glucosilceramida sintasa.
TW201613639A (en) Methods for treating cardiovascular diseases
MX2020013865A (es) Tratamiento genico combinatorio.
MX2013015357A (es) Terapia de combinacion.